$UPC
Universe Pharmaceuticals Inc Stock $upc

$upc Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 20-F Financial Statement

#000121390024007745 Filed on January 30, 2024

Income Statement

Concept	2023 Q3	2023
Revenue	$13.84M	$32.31M
YoY Change	-13.17%	-19.52%
Cost Of Revenue	$9.655M	$21.99M
YoY Change	23.68%	20.5%
Gross Profit	$4.187M	$10.32M
YoY Change	-48.53%	-52.88%
Gross Profit Margin	30.25%	31.93%
Selling, General & Admin	$5.273M	$8.983M
YoY Change	-51.06%	-58.57%
% of Gross Profit	125.93%	87.09%
Research & Development	$2.590M	$4.859M
YoY Change	-65.46%	-36.44%
% of Gross Profit	61.86%	47.1%
Depreciation & Amortization	$251.0K	$508.8K
YoY Change	3.79%	-4.71%
% of Gross Profit	5.99%	4.93%
Operating Expenses	$7.863M	$13.84M
YoY Change	-56.97%	-52.81%
Operating Profit	-$3.676M	-$3.527M
YoY Change	-63.75%	-52.59%
Interest Expense	-$51.15K	$156.8K
YoY Change	44.41%	-3.46%
% of Operating Profit
Other Income/Expense, Net	-$381.3K	-$322.8K
YoY Change	-65.91%	-40.81%
Pretax Income	-$4.109M	-$3.850M
YoY Change	-63.62%	-51.78%
Income Tax	$1.339M	$2.313M
% Of Pretax Income
Net Earnings	-$5.448M	-$6.163M
YoY Change	-47.96%	-29.46%
Net Earnings / Revenue	-39.36%	-19.08%
Basic Earnings Per Share		-$1.70
Diluted Earnings Per Share	-$1.50	-$1.70
COMMON SHARES
Basic Shares Outstanding	3.646M shares	3.625M shares
Diluted Shares Outstanding		3.625M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.50M		$18.50M
YoY Change	-1.89%		223.98%
Cash & Equivalents	$5.285M
Short-Term Investments	$13.22M		$13.22M
Other Short-Term Assets	$4.295M		$4.295M
YoY Change	-18.27%		-76.66%
Inventory	$3.343M		$3.343M
Prepaid Expenses
Receivables	$10.67M		$10.67M
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$36.81M		$36.81M
YoY Change	-11.31%		-11.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.700M		$12.79M
YoY Change	-12.96%		-5.77%
Goodwill
YoY Change
Intangibles	$148.6K
YoY Change	-5.63%
Long-Term Investments	$685.3K		$685.3K
YoY Change	-2.5%		-2.5%
Other Assets	$2.850M		$2.850M
YoY Change	-20.77%		-20.77%
Total Long-Term Assets	$16.48M		$16.48M
YoY Change	-8.64%		-8.64%
TOTAL ASSETS
Total Short-Term Assets	$36.81M		$36.81M
Total Long-Term Assets	$16.48M		$16.48M
Total Assets	$53.29M		$53.29M
YoY Change	-10.5%		-10.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.585M		$4.585M
YoY Change	49.1%		49.1%
Accrued Expenses	$2.712M		$2.712M
YoY Change	6.79%		6.79%
Deferred Revenue
YoY Change
Short-Term Debt	$1.371M	$411.2K	$5.482M
YoY Change	-65.18%		-25.06%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.75M		$13.75M
YoY Change	5.01%		5.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.75M		$13.75M
Total Long-Term Liabilities	$0.00		$0.00
Total Liabilities	$13.75M		$13.75M
YoY Change	5.01%		5.01%
SHAREHOLDERS EQUITY
Retained Earnings	$10.16M
YoY Change	-37.76%
Common Stock	$29.35M
YoY Change	43077.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.53M		$39.53M
YoY Change
Total Liabilities & Shareholders Equity	$53.29M		$53.29M
YoY Change	-10.5%		-10.5%

Cashflow Statement

Concept	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$5.448M	-$6.163M
YoY Change	-47.96%	-29.46%
Depreciation, Depletion And Amortization	$251.0K	$508.8K
YoY Change	3.79%	-4.71%
Cash From Operating Activities	-$3.679M	$1.120M
YoY Change	-50.49%	-185.35%
INVESTING ACTIVITIES
Capital Expenditures	$43.52K	$44.17K
YoY Change	14.32%	-52.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$43.52K	-$44.17K
YoY Change	-98.87%	-98.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.472M	-$1.391M
YoY Change	-204.0%	-141.91%
NET CHANGE
Cash From Operating Activities	-3.679M	$1.120M
Cash From Investing Activities	-43.52K	-$44.17K
Cash From Financing Activities	-3.472M	-$1.391M
Net Change In Cash	-7.194M	-$426.2K
YoY Change	-9.46%	-81.99%
FREE CASH FLOW
Cash From Operating Activities	-$3.679M	$1.120M
Capital Expenditures	$43.52K	$44.17K
Free Cash Flow	-$3.722M	$1.076M
YoY Change	-50.16%	-176.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40231
CY2023	dei	Entity Registrant Name EntityRegistrantName	Universe Pharmaceuticals INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	265 Jingjiu Avenue,
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Jinggangshan Economic and Technological Development Zone
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ji’an, Jiangxi
CY2023	dei	Entity Address Country EntityAddressCountry	CN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	343100
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares
CY2023	dei	Trading Symbol TradingSymbol	UPC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3645974	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Name AuditorName	YCM CPA, Inc.
CY2023	dei	Auditor Firm AuditorFirmId	6781
CY2023	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q3	us-gaap	Cash Cash	5285247	usd
CY2022Q3	us-gaap	Cash Cash	5711458	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	13219005	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	13148594	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10667603	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15183890	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	3343266	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2206488	usd
CY2023Q3	us-gaap	Supplies Supplies	180643	usd
CY2022Q3	us-gaap	Supplies Supplies	16701	usd
CY2023Q3	upc	Prepayment For Acquisition Current PrepaymentForAcquisitionCurrent	3426535	usd
CY2022Q3	upc	Prepayment For Acquisition Current PrepaymentForAcquisitionCurrent	3514450	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	626241	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1724099	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	36810218	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	41505680	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3699965	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4250638	usd
CY2023Q3	upc	Prepayments Made To A Related Party For Purchase Of Property Non Current PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent	2192982	usd
CY2022Q3	upc	Prepayments Made To A Related Party For Purchase Of Property Non Current PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent	2249248	usd
CY2023Q3	upc	Prepayments For Construction In Progress PrepaymentsForConstructionInProgress	9092996	usd
CY2022Q3	upc	Prepayments For Construction In Progress PrepaymentsForConstructionInProgress	9326296	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148584	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	157451	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	685307	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	702890	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	656980	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1347672	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	16476814	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	18034195	usd
CY2023Q3	us-gaap	Assets Assets	53287032	usd
CY2022Q3	us-gaap	Assets Assets	59539875	usd
CY2023Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	5482456	usd
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3936184	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4585285	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3075393	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	434758	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	167350	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2711736	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2539362	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13754331	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13097552	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01875
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01875
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3625000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3625000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3625000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3625000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	67969	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	67969	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29279159	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29279159	usd
CY2023Q3	upc	Statutory Reserve StatutoryReserve	2439535	usd
CY2022Q3	upc	Statutory Reserve StatutoryReserve	2439535	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	10159304	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	16322365	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2413266	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1666705	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	39532701	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46442323	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53287032	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59539875	usd
CY2023	us-gaap	Revenues Revenues	32308735	usd
CY2022	us-gaap	Revenues Revenues	40143151	usd
CY2021	us-gaap	Revenues Revenues	47982031	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	21993601	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	18251815	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	22655854	usd
CY2023	us-gaap	Gross Profit GrossProfit	10315134	usd
CY2022	us-gaap	Gross Profit GrossProfit	21891336	usd
CY2021	us-gaap	Gross Profit GrossProfit	25326177	usd
CY2023	us-gaap	Selling Expense SellingExpense	6783703	usd
CY2022	us-gaap	Selling Expense SellingExpense	19083135	usd
CY2021	us-gaap	Selling Expense SellingExpense	2973531	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2199657	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2602624	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3296844	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4858548	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7644375	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5465662	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13841908	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	29330134	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11736037	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3526774	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-7438798	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13590140	usd
CY2023	us-gaap	Interest Expense InterestExpense	156788	usd
CY2022	us-gaap	Interest Expense InterestExpense	162400	usd
CY2021	us-gaap	Interest Expense InterestExpense	101604	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-235614	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	48940	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-80434	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	38530	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	-470477	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	239549	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	31072	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	38588	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	30827	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-322800	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-545349	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88338	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3849574	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7984147	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13678478	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2313487	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	752419	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2358526	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6163061	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8736566	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	11319952	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	746561	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	3755464	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1193369	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6909622	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12492030	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12513321	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.7
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.41
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.58
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3625000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3625000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3163470	shares
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	20802904	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28750000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	31436	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1120082	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1312346	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2055847	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44169	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	93703	usd
CY2021	upc	Stock Issued During Period Value Capitalized Initial Public Offering Costs StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts	-3131872	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	11319952	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1193369	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	58934353	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8736566	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3755464	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46442323	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6163061	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-746561	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	39532701	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6163061	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8736566	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	11319952	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	508785	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	533949	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	446878	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-114	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-983	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1559	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-439327	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	419353	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-230175	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-49166	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	15774	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	679586	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-605278	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-668341	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	38530	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	-470477	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	239549	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4718118	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1549312	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3867457	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1183823	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-16586	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	451634	usd
CY2023	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	170016	usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-2681214	usd
CY2021	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	2717085	usd
CY2022	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising	-7385695	usd
CY2021	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising	7434240	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-236982	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	237720	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1091022	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1699929	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	168188	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1641426	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1896621	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2457337	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	280939	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-904127	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-298620	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	244015	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2318474	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	444505	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	523	usd
CY2021	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty	2457600	usd
CY2021	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction	10629120	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3814925	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15330660	usd
CY2021	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments	1801927	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44169	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3908105	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27059958	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	5671104	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4272716	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4300800	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	3969773	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	4272716	usd
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2764800	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28750000	usd
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2792543	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-3091977	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	3317943	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-911648	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1390646	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3317943	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26581809	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-111478	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-463942	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	553702	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-426211	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2366450	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1980294	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5711458	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8077908	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10058202	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5285247	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5711458	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8077908	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	190184	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	199852	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	149303	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	863800	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	2748629	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	3271219	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Universe Pharmaceuticals Inc. (“Universe INC” or the “Company”) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company with limited liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Universe INC owns 100% equity interest of Universe Pharmaceuticals (International) Group (“Universe HK”), an entity incorporated on May 21, 2014 in accordance with the laws and regulations in Hong Kong.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Universe INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Jiangxi Universe Pharmaceuticals Co., Ltd. (“Jiangxi Universe”) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), which was incorporated on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b><i>Reorganization</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">A reorganization of the Company’s legal structure (the “Reorganization”) was completed on December 11, 2019. The Reorganization involved the incorporation of Universe INC and Universe Technology, and the transfer of 100% of the equity interests of Jiangxi Universe to Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Reorganization has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders controlled all these entities before and after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements. Results of operations for the periods presented comprise those of the previously separate entities combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On March 25, 2021, the Company closed its initial public offering (the “IPO”) of 5,000,000 ordinary shares, par value $0.003125 per share (the “ordinary shares”) at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds from the IPO totaled $28.75 million. Net proceeds of the IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, the Company’s ordinary shares began trading on the Nasdaq Global Market under the symbol “UPC” on March 23, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">On May 12, 2021, through the Company’s PRC subsidiary, Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou Universe Hanhe Medical Research Co., Ltd. (“Universe Hanhe”) in Guangzhou City, China, for the business purpose of conducting research and development of new pharmaceutical products in order to diversify the Company’s product offerings in the near future. As of September 30, 2023 and as of the date of this report, Universe Hanhe has no active business operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">(a)</td><td style="text-align: justify">with immediate effect, to increase the Company’s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">(b)</td><td style="text-align: justify">that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company (the “Share Consolidation”); and</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">(c)</td><td style="text-align: justify">that, upon the effectiveness of the Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out in Annex B in the proxy statement dated 24 May 2023, in substitution for and to the exclusion of, the memorandum of association of the Company in effect immediately prior to effectiveness of the Share Consolidation.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The board of directors of the Company resolved to effect the Share Consolidation on July 27, 2023 with the authorized, issued and outstanding shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875 per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000 ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share. The Company’s consolidated financial statements were retrospectively restated for effect of the 6-for-1 share consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">Details of the subsidiaries of the Company as of September 30, 2023 are set out below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center">Date of</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center">Place of</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center">% of</td><td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Name of Entity</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Incorporation</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Incorporation</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Ownership</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal Activities</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Universe INC</td><td> </td> <td style="vertical-align: top; text-align: center">December 11, 2019</td><td> </td> <td style="vertical-align: top; text-align: center">Cayman Islands</td><td> </td> <td style="vertical-align: top; text-align: center">Parent, 100%</td><td> </td> <td style="vertical-align: top; text-align: center">Investment holding</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 25%; text-align: left">Universe HK</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 18%; text-align: center">May 21, 2014</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 15%; text-align: center">Hong Kong</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 10%; text-align: center">100%</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 28%; text-align: center">Investment holding</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Universe Technology</td><td> </td> <td style="vertical-align: top; text-align: center">April 18, 2019</td><td> </td> <td style="vertical-align: top; text-align: center">PRC</td><td> </td> <td style="vertical-align: top; text-align: center">100%</td><td> </td> <td style="vertical-align: top; text-align: center">WFOE, Investment holding</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Jiangxi Universe</td><td> </td> <td style="vertical-align: top; text-align: center">March 2, 1998</td><td> </td> <td style="vertical-align: top; text-align: center">PRC</td><td> </td> <td style="vertical-align: top; text-align: center">100%</td><td> </td> <td style="vertical-align: top; text-align: center">Research and development and manufacturing of modernized traditional Chinese medicines</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Universe Trade</td><td> </td> <td style="vertical-align: top; text-align: center">March 10, 2010</td><td> </td> <td style="vertical-align: top; text-align: center">PRC</td><td> </td> <td style="vertical-align: top; text-align: center">100%</td><td> </td> <td style="vertical-align: top; text-align: center">Sales of modernized traditional Chinese medicines</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Universe Hanhe</td><td> </td> <td style="vertical-align: top; text-align: center">May 12, 2021</td><td> </td> <td style="vertical-align: top; text-align: center">PRC</td><td> </td> <td style="vertical-align: top; text-align: center">100%</td><td> </td> <td style="vertical-align: top; text-align: center">Research and development of new pharmaceutical products</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines derivatives (“TCMD”) products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces products and dietary supplements (collectively, “third-party products”). All of these TCMD and third-party products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.</span></p>
CY2021Q1	upc	Public Offering Price PublicOfferingPrice	5
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	16666666.6666	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01875
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b><i>Uses of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability of advance to suppliers, inventory valuations, useful lives of property and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The business operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.</span></p>
CY2023	upc	Allowance For Uncollectable Balances Amount AllowanceForUncollectableBalancesAmount	347306	usd
CY2022	upc	Allowance For Uncollectable Balances Amount AllowanceForUncollectableBalancesAmount	791827	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	69747	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	120286	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5465662	usd
CY2023	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	685307	usd
CY2023	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	5000000	cny
CY2022	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	702890	usd
CY2022	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	5000000	cny
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	31072	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	38588	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	30827	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4858548	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7644375	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	4653633	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	17527318	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1316654	usd
CY2023	upc	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023	upc	Percentage Of Vat Rate PercentageOfVatRate	0.13	pure
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	440962	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	465689	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	617145	usd
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	11014909	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	15975717	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	347306	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	791827	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10667603	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15183890	usd
CY2023Q3	upc	Net Account Receivable Percentage NetAccountReceivablePercentage	0.586	pure
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	6.5	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	791827	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	446527	usd
CY2022	upc	Allowance For Doubtful Accounts Additions AllowanceForDoubtfulAccountsAdditions	419353	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	439327	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5194	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	74053	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	347306	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	791827	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	635395	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	989043	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2777617	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1337731	usd
CY2023Q3	us-gaap	Inventory Adjustments InventoryAdjustments	69746	usd
CY2022Q3	us-gaap	Inventory Adjustments InventoryAdjustments	120286	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	3343266	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2206488	usd
CY2023	upc	Schedule Of Advances To Suppliers Net ScheduleOfAdvancesToSuppliersNet	<span style="background-color: white">Advances to suppliers consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>As of September 30,</b></span></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Advances to suppliers for inventory raw material purchase</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-size: 10pt">180,643</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 9%; text-align: right"><span style="font-size: 10pt">16,701</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: allowance for doubtful accounts</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-size: 10pt">-</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-size: 10pt">-</span></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Advances to suppliers</span></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">180,643</span></td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">16,701</span></td> <td style="padding-bottom: 4pt"> </td></tr> </table>
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	180643	usd
CY2022Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	16701	usd
CY2023Q3	us-gaap	Supplies Supplies	180643	usd
CY2022Q3	us-gaap	Supplies Supplies	16701	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	25000000	cny
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3400000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	13148594	usd
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	13725204	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	38530	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-470477	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	31881	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-106133	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	13219005	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	13148594	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	38530	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	-470477	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	239549	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9750445	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9960736	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6050480	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5710098	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3699965	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4250638	usd
CY2023	us-gaap	Depreciation Depreciation	503687	usd
CY2022	us-gaap	Depreciation Depreciation	528919	usd
CY2021	us-gaap	Depreciation Depreciation	441355	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	114	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	983	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1559	usd
CY2021Q2	upc	Percentage Of Total Purchase Price Payable PercentageOfTotalPurchasePricePayable	0.20	pure
CY2021Q2	upc	Payable Delivery Property Percentage PayableDeliveryPropertyPercentage	0.30	pure
CY2023	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	16000000	cny
CY2023	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	2200000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	267121	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	273974	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	118537	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	116523	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148584	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	157451	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5098	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5030	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5523	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4929	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4929	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4929	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4929	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4929	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	123939	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148584	usd
CY2023	upc	Capital Expenditure CapitalExpenditure	3400000	usd
CY2023Q3	upc	Future Minimum Capital Expenditure Next Twelve Monhs FutureMinimumCapitalExpenditureNextTwelveMonhs	3392270	usd
CY2023Q3	upc	Future Minimum Capital Expenditure Two Years FutureMinimumCapitalExpenditureTwoYears	8607456	usd
CY2023Q3	upc	Future Minimum Capital Expenditure Three Years FutureMinimumCapitalExpenditureThreeYears	1130756	usd
CY2023Q3	upc	Capital Expenditure Net CapitalExpenditureNet	13130482	usd
CY2021Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	2749.3	sqm
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	32000000	cny
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	4400000	usd
CY2021Q2	upc	Percentage Of Prepayment PercentageOfPrepayment	0.50	pure
CY2023Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	5482456	usd
CY2022Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3936184	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	9000000	cny
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1233553	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	3000000	cny
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	411184	usd
CY2023Q2	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.05	pure
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	10000000	cny
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1370614	usd
CY2023Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0425	pure
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	190184	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	199852	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	149303	usd
CY2021Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	2749.3	sqm
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	32000000	cny
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	4400000	usd
CY2023	upc	Prepayment Amount PrepaymentAmount	16000000	cny
CY2023	upc	Prepayment Amount PrepaymentAmount	2200000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.041	pure
CY2023	upc	Preferential Tax Treatment Description PreferentialTaxTreatmentDescription	Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one of the Company’s main operating subsidiaries in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning November 2016 with a term of three years. In December 2019 and November 2022, Jiangxi Universe successfully renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15% for three years, respectively, through November 2025. Universe Trade, another operating subsidiary of the Company in the PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning December 2020 with a term of three years through December 2023. Universe Trade did not successfully renew its HNTE status at the end of December 2022 and, therefore, will be subject to the standard PRC enterprise income tax rate of 25% starting from January 2024. EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years ended September 30, 2023, 2022 and 2021 were reported at a blended reduced rate as a result of certain of the PRC subsidiaries of the Company’s being approved as a HNTE and enjoying a 15% reduced income tax rate.
CY2023Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	309840	usd
CY2022Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	694955	usd
CY2021Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1518979	usd
CY2023	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.09
CY2022	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.19
CY2021	us-gaap	Income Tax Holiday Income Tax Benefits Per Share IncomeTaxHolidayIncomeTaxBenefitsPerShare	0.48
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	685937	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1357697	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3026867	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2313487	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	752419	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2358526	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.081	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.087	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.11	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.223	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.034	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.02	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.141	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.048	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.094	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.171	pure
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	590283	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1210855	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	66697	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	136817	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	656980	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1347672	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	656980	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1347672	usd
CY2023Q3	upc	Value Added Tax Payable ValueAddedTaxPayable	303713	usd
CY2022Q3	upc	Value Added Tax Payable ValueAddedTaxPayable	115087	usd
CY2023Q3	upc	Other Taxes Payable OtherTaxesPayable	131045	usd
CY2022Q3	upc	Other Taxes Payable OtherTaxesPayable	52263	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	434758	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	167350	usd
CY2023Q3	us-gaap	Foreign Financial Institutions Mandated Deposits ForeignFinancialInstitutionsMandatedDeposits	5223573	usd
CY2022Q3	us-gaap	Foreign Financial Institutions Mandated Deposits ForeignFinancialInstitutionsMandatedDeposits	5711423	usd
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.003125
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3625000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3625000	shares
CY2022Q3	upc	Equity Method Investment Ownerships Percentage EquityMethodInvestmentOwnershipsPercentage	1.10	pure
CY2023	upc	Reserve Is Equal Percentage ReserveIsEqualPercentage	0.50	pure
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2023	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments		usd
CY2022	upc	Redemption Of Shortterm Investments RedemptionOfShorttermInvestments		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	upc	Future Minimum Capital Expenditure FutureMinimumCapitalExpenditure	13100000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3400000	usd
CY2021Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	2749.3	sqm
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	32000000	cny
CY2021Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	4400000	usd
CY2023Q3	upc	Minority Interests Ownership Percentage By Parent MinorityInterestsOwnershipPercentageByParent	0.25	pure
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.41
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.58
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3163470	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3625000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3625000	shares
CY2021	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge		usd
CY2023	us-gaap	Increase Decrease In Prepaid Advertising IncreaseDecreaseInPrepaidAdvertising		usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2023	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty		usd
CY2022	upc	Prepayments Made To A Related Party For Purchase Of Property PrepaymentsMadeToARelatedPartyForPurchaseOfProperty		usd
CY2023	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction		usd
CY2022	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction		usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2023	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering		usd
CY2023	upc	Allowance For Doubtful Accounts Additions AllowanceForDoubtfulAccountsAdditions		usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries		usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance		pure
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001809616

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-24-007745-index-headers.html	Edgar Link	pending
0001213900-24-007745-index.html	Edgar Link	pending
0001213900-24-007745.txt	Edgar Link	pending
0001213900-24-007745-xbrl.zip	Edgar Link	pending
ex1-1_001.jpg	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex15-2_001.jpg	Edgar Link	pending
ex4-10_001.jpg	Edgar Link	pending
ex4-10_002.jpg	Edgar Link	pending
ex4-10_003.jpg	Edgar Link	pending
ex4-11_001.jpg	Edgar Link	pending
ex4-11_002.jpg	Edgar Link	pending
ex4-11_003.jpg	Edgar Link	pending
ex4-11_004.jpg	Edgar Link	pending
ex4-6_001.jpg	Edgar Link	pending
ex4-6_002.jpg	Edgar Link	pending
ex4-6_003.jpg	Edgar Link	pending
ex4-6_004.jpg	Edgar Link	pending
ex4-6_005.jpg	Edgar Link	pending
ex4-6_006.jpg	Edgar Link	pending
ex4-6_007.jpg	Edgar Link	pending
ex4-7_001.jpg	Edgar Link	pending
ex4-7_002.jpg	Edgar Link	pending
ex4-7_003.jpg	Edgar Link	pending
ex4-7_004.jpg	Edgar Link	pending
ex4-7_005.jpg	Edgar Link	pending
ex4-7_006.jpg	Edgar Link	pending
ex4-7_007.jpg	Edgar Link	pending
ex4-7_008.jpg	Edgar Link	pending
ex4-8_001.jpg	Edgar Link	pending
ex4-8_002.jpg	Edgar Link	pending
ex4-8_003.jpg	Edgar Link	pending
f20f2023ex1-1_universe.htm	Edgar Link	pending
f20f2023ex11-2_universe.htm	Edgar Link	pending
f20f2023ex12-1_universe.htm	Edgar Link	pending
f20f2023ex12-2_universe.htm	Edgar Link	pending
f20f2023ex13-1_universe.htm	Edgar Link	pending
f20f2023ex13-2_universe.htm	Edgar Link	pending
f20f2023ex15-1_universe.htm	Edgar Link	pending
f20f2023ex15-2_universe.htm	Edgar Link	pending
f20f2023ex2-1_universe.htm	Edgar Link	pending
f20f2023ex2-3_universe.htm	Edgar Link	pending
f20f2023ex4-10_universe.htm	Edgar Link	pending
f20f2023ex4-11_universe.htm	Edgar Link	pending
f20f2023ex4-6_universe.htm	Edgar Link	pending
f20f2023ex4-7_universe.htm	Edgar Link	pending
f20f2023ex4-8_universe.htm	Edgar Link	pending
f20f2023ex97-1_universe.htm	Edgar Link	pending
f20f2023_universe.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
f20f2023_universe_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
upc-20230930.xsd	Edgar Link	pending
upc-20230930_cal.xml	Edgar Link	unprocessable
upc-20230930_def.xml	Edgar Link	unprocessable
upc-20230930_pre.xml	Edgar Link	unprocessable
upc-20230930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UPC
Universe Pharmaceuticals Inc Stock $upc

2023 Q3 Form 20-F Financial Statement

#000121390024007745 Filed on January 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPC Universe Pharmaceuticals Inc Stock $upc

2023 Q3 Form 20-F Financial Statement

#000121390024007745 Filed on January 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPC
Universe Pharmaceuticals Inc Stock $upc